Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.

SE(3) Equivariant Topologies for Structure-based Drug Discovery

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Multimodal Protein-Ligand Contrastive Pretraining for Effective and Efficient Drug Discovery

SynthFormer: Equivariant Pharmacophore-based Generation of Molecules for Ligand-Based Drug Design

EquiBind: Geometric Deep Learning for Drug Binding Structure Prediction

Equivariant Flexible Modeling of the Protein-Ligand Binding Pose with Geometric Deep Learning.

Fragment-Based Ligand Generation Guided By Geometric Deep Learning On Protein-Ligand Structure

Improving the generalizability of protein-ligand binding predictions with AI-Bind

Leveraging nonstructural data to predict structures and affinities of protein-ligand complexes

In-Pocket 3D Graphs Enhance Ligand-Target Compatibility in Generative Small-Molecule Creation

Synthesis-driven design of 3D molecules for structure-based drug discovery using geometric transformers

Leveraging non-structural data to predict structures of protein–ligand complexes

Protein-Ligand Complex Generator & Drug Screening via Tiered Tensor Transform

ERL‐ProLiGraph: Enhanced representation learning on protein‐ligand graph structured data for binding affinity prediction

Binding Affinity Prediction with 3D Machine Learning: Training Data and Challenging External Testing

Optimization of binding affinities in chemical space with generative pre-trained transformer and deep reinforcement learning

Leveraging binding-site structure for drug discovery with point-cloud methods

Boosting Convolutional Neural Networks' Protein Binding Site Prediction Capacity Using SE(3)-invariant transformers, Transfer Learning and Homology-based Augmentation

Development and evaluation of a deep learning model for protein-ligand binding affinity prediction

Improving detection of protein-ligand binding sites with 3D segmentation

Deep Learning-Based Modeling of Drug–Target Interaction Prediction Incorporating Binding Site Information of Proteins